SummitTX Capital L.P. Takes $1.32 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

SummitTX Capital L.P. purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 1st quarter, Holdings Channel reports. The fund purchased 1,713 shares of the biopharmaceutical company’s stock, valued at approximately $1,324,000.

Other institutional investors also recently bought and sold shares of the company. WPG Advisers LLC increased its position in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares during the last quarter. SHP Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $26,000. Titan Wealth CI Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $29,000. Kemnay Advisory Services Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. Finally, Birchwood Financial Partners Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $32,000. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on REGN. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a report on Tuesday, July 7th. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $995.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. TD Cowen boosted their target price on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research report on Thursday, April 23rd. Leerink Partners reaffirmed a “market perform” rating and set a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Finally, Sanford C. Bernstein reduced their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $787.88.

Regeneron Pharmaceuticals Trading Up 0.0%

NASDAQ REGN opened at $695.42 on Thursday. The stock has a market cap of $73.52 billion, a PE ratio of 16.94, a PEG ratio of 27.77 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $821.11. The company’s 50-day moving average price is $638.74 and its 200-day moving average price is $711.76. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter last year, the business posted $8.22 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 2.06 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Potentially solid quarterly results: Investors are looking for continued growth from Dupixent, Eylea HD and Libtayo, along with updates on buybacks and Regeneron’s development pipeline. The prior quarter showed strong momentum, with revenue rising 19% year over year and EPS exceeding analyst expectations. Regeneron To Report Earnings Tomorrow
• Positive Sentiment: Partnered Arcalyst momentum: Kiniksa Pharmaceuticals exceeded second-quarter expectations, supported by sales of Arcalyst, which is partnered with Regeneron. The update may reinforce confidence in the commercial performance and royalty contribution of the collaboration, although the impact on REGN is indirect. Kiniksa Tops Q2 Estimates on Regeneron-Partnered Arcalyst
• Neutral Sentiment: Earnings are the next major catalyst: Regeneron is scheduled to report before the market opens Thursday. Investors will focus on product sales, full-year guidance, pipeline commentary and management’s response to the recent clinical setback. Regeneron to Announce Earnings on Thursday
• Negative Sentiment: Failed melanoma trial and litigation overhang: Multiple law firms announced or promoted securities class actions alleging that Regeneron and executives misled investors about the Phase 3 Fianlimab-Libtayo trial, including its protocol changes and clinical differentiation. The trial failure reportedly caused a sharp selloff and an approximately $11 billion loss in market value. The lawsuits themselves may not create an immediate cash liability, but they add reputational, legal and pipeline risk. Investors have until September 14, 2026, to seek lead-plaintiff status. Regeneron Investor Alert

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.